Arcturus Therapeutics Holdings Inc.
ARCT
Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis tranā¦ read more
Healthcare
Biotechnology
12 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$6.53
Price+1.56%
$0.10
1Y
Price
Market Cap
$177.136m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-74.0%
EBITDA Margin-78.4%
Net Profit Margin-101.1%
Free Cash Flow MarginRevenue
$92.043m
-33.5%
1y CAGR-23.0%
3y CAGR+373.9%
5y CAGREarnings
-$66.709m
+17.6%
1y CAGR-190.9%
3y CAGR-117.0%
5y CAGREPS
-$2.46
+18.0%
1y CAGR-189.9%
3y CAGR-116.3%
5y CAGRBook Value
$224.559m
$282.343m
Assets$57.784m
Liabilities$21.865m
DebtDebt to Assets
7.7%
-0.3x
Debt to EBITDAFree Cash Flow
-$58.646m
+2.9%
1y CAGR-123.7%
3y CAGR-63.4%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company